Giltertinib is effective for sorafenib-resistant post-transplant relapse of FLT3-ITD positive AML

Ryo Akazawa

Presentation information

Poster Session

Sat.Oct,12

Poster Session 2-6 AML: FLT3 Inhibitors

Sat. Oct 12, 2019 5:10 PM - 5:45 PM Poster (Tokyo International Forum, B2F Hall E)

Chair: Masahiro Onozawa (Hokkaido University Hospital, Department of Hematology)

[PS2-6-4] Giltertinib is effective for sorafenib-resistant post-transplant relapse of FLT3-ITD positive AML

Ryo Akazawa¹, Itaru Kato¹, Tatsuya Kamitori¹, Keiji Tasaka¹, Kiyotaka Isobe¹, Katsutsugu Umeda¹, Hidefumi Hiramatsu¹, Souichi Adachi², Junko Takita¹ (1.Pediatrics, Kyoto Univ., Kyoto, Japan, 2.Human Health Sciences, Kyoto Univ., Kyoto, Japan)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.